Financial Daily from THE HINDU group of publications
Tuesday, Nov 09, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements


JB Chem launches new product

Our Bureau

MUMBAI: J.B. Chemicals & Pharmaceuticals Limited (JBCPL) has launched Magnilek, a diagnostic product used as a contrast media for MRI in the diagnosis of neurological diseases and cancer.

The product has been developed by J.B. Chemical's in-house research division and manufactured at its facility, the company said.

JBCPL already has a presence in the Rs 100 crore domestic diagnostics segment under the brand names Trazograf and Lek-pamidol. According to the company, the new product has a business potential in the export market.

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
K Sera Sera plans to raise Rs 100 cr — International film project on cards


GE sells 60% stake in BPO arm for $500 m
Petronet India to be sold by March
Festival freebies from car cos
NCCL bags Rs 302-cr orders
JB Chem launches new product
Conversion of MNC arm into public co — `Concept paper proposal needs to be modified'
How Deloitte tackled attrition among women
Titan revamps Europe operations — To focus only on 4 markets, to exit from 8
Essilor to acquire Vijay Vision
Excise sops lure pharma, FMCG firms to the hills
Birla group plans to set up 30 ready-mix concrete plants
Call for clarity in definition of promoter
`We hope to achieve Rs 1,200 cr turnover this year'
Jessop to diversify into shipbuilding
Dabhol revival package likely by next month
Orchid Chem eyes $1-b turnover
`Delayed resolution of Dabhol no impact on GE's plans for India'
Alan Sheppard to head Dr Reddy's Europe generics business



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line